Association of Risk of Incident Venous Thromboembolism With Atopic Dermatitis and Treatment With Janus Kinase Inhibitors

Authors:

Abstract
Atopic dermatitis (AD) is a prevalent inflammatory dermatosis with increasing worldwide prevalence.1,2 Symptoms, such as relapsing pruritus and visible lesions, may last for a few years and even persist throughout life, necessitating effective treatments.3,4 Janus kinase (JAK) inhibitors have become a promising treatment option for patients with AD because they have been associated with favorable clinical outcomes in clinical trials.5

This publication has 59 references indexed in Scilit: